Read by QxMD icon Read

dialysis. ckd

Eun-Ho Lee, Sung-Cheol Yun, Ye-Ji Lim, Jun-Young Jo, Dae-Kee Choi, In-Cheol Choi
We assessed whether perioperative fluid management with balanced solutions and a limited volume of hydroxyethyl starch (renal-protective fluid management [RPF] strategy) could improve renal outcomes after cardiovascular surgery.For this retrospective observational study, we evaluated 2613 patients who underwent cardiovascular surgery from January 1, 2010 to December 31, 2013. The control group were given intravenous fluids with saline-based solutions and unlimited volumes of hydroxyethyl starch solutions and the RPF group were given intravenous fluids with RPF...
February 2019: Medicine (Baltimore)
Hongyong Liu, Yuqiu Ye, Yanbing Chen, Yunqiang Zhang, Shaomin Li, Wentao Hu, Rongqian Yang, Zhesi Zhang, Hongquan Peng, Linsheng Lv, Xun Liu
Anemia is one of the major complications in predialysis patients with chronic kidney disease (CKD). A clearer cognition of the prognostic impact of hemoglobin (Hb) or hematocrit (Hct) target on the outcomes of predialysis patients with CKD is significant. This article aims to establish the suitable hemoglobin target to provide clinical guidance. MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather researches that assessed all-cause mortality, stroke, treatment of renal replacement, and transfusion...
February 11, 2019: Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research
Lucia Del Vecchio, Ivano Baragetti, Francesco Locatelli
Statins and ezetimibe effectively reduce the burden of cardiovascular (CV) disease in patients with chronic kidney disease (CKD). Unfortunately, many subjects still die or have CV events despite cholesterol-lowering therapy. This is particularly true in patients with more advanced CKD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that induces the degradation of the low-density lipoprotein receptor by targeting it for lysosomal destruction. Its inhibition causes a dramatic fall in cholesterol levels on top of maximized statin therapy...
February 11, 2019: Nephrology, Dialysis, Transplantation
Tair Ben-Porat, Anat Weiss-Sadan, Amihai Rottenstreich, Shiri Sherf-Dagan, Chaya Schweiger, Irit Mor Yosef-Levi, Dana Weiner, Odile Azulay, Nasser Sakran, Rivki Harari, Ram Elazary
Bariatric surgery (BS) may be effective for chronic kidney disease (CKD) patients by reducing microalbuminuria and proteinuria, and by facilitating their meeting inclusion criteria for kidney transplantation. However, nutritional management for this population is complex and specific guidelines are scarce. A literature search was performed to create dietetic practice for these patients based on the most recent evidence. For the purposes of nutritional recommendations, we divided the patients into 2 subgroups: 1) patients with CKD and dialysis, and 2) patients after kidney transplantation...
January 1, 2019: Advances in Nutrition
Zlatana Nenova, John Hotchkiss
BACKGROUND: Chronic kidney disease palliative care guidelines would benefit from more diverse and objectively defined health status measures. AIM: The aim is to identify high-risk patients from administrative data and facilitate timely and uniform palliative care involvement. DESIGN: It is a retrospective cohort study. SETTING/PARTICIPANTS: In total, 45,368 Veterans, with chronic kidney disease Stage 3, 4, or 5, were monitored for up to 6 years and categorized into three groups, based on whether they died, started dialysis, or avoided both outcomes...
February 12, 2019: Palliative Medicine
Louis Holdstock, Borut Cizman, Amy M Meadowcroft, Nandita Biswas, Brendan M Johnson, Delyth Jones, Sung Gyun Kim, Steven Zeig, John J Lepore, Alexander R Cobitz
Background: This study assessed the short-term safety and efficacy of daprodustat (an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor) to achieve a target hemoglobin in patients with anemia of chronic kidney disease (CKD). Methods: Patients ( n  = 252) with Stages 3-5 CKD not receiving dialysis were enrolled in this 24-week, multicenter trial [hemoglobin entry criteria: 8-10 g/dL (Cohort 1) or 8-11 g/dL (Cohort 2) for recombinant human erythropoietin (rhEPO)-naïve participants; 9-10...
February 2019: Clinical Kidney Journal
Alberto Ortiz, Maria Dolores Sanchez-Niño
Sarcopenia and frailty are recognized as key risk factors for adverse outcomes in patients on renal replacement therapy or with non-dialysis chronic kidney disease (CKD). However, there is still debate about their pathogenesis and, thus, about the best therapeutic approaches, as well as the impact on outcomes of current approaches based on different exercise programmes. In the past two issues of Clinical Kidney Journal , several manuscripts address the issue of sarcopenia in CKD from the point of view of pathogenesis and new therapeutic approaches, monitoring of results, implementation of exercise programmes and specific potential benefits of exercise programmes in dialysis and non-dialysis CKD patients, as assessed by clinical trials...
February 2019: Clinical Kidney Journal
Yen-Ling Chiu, Hsiu-Hui Tsai, Yen-Jun Lai, Hsin-Yi Tseng, Yen-Wen Wu, Yu-Sen Peng, Cheng-Ming Chiu, Yi-Fang Chuang
BACKGROUND: Chronic kidney disease exhibits a prominent premature aging phenotype in many different organ systems, including the brain. Nevertheless, a comprehensive characterization of brain aging in non-demented patients with end-stage renal disease (ESRD) is lacking and it remains unclear if the collective changes of cognitive functions and brain structures in ESRD is compatible with aging. METHODS: We compared 56 non-demented, independently living dialysis patients (mean age 59...
February 7, 2019: Journal of the Formosan Medical Association, Taiwan Yi Zhi
Aníbal Ferreira, Bruno Pinto, David Navarro, João Aniceto, Pedro L Neves, Pedro Ponce
INTRODUCTION: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group. OBJECTIVE: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden...
February 4, 2019: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Po-Hua Huang, Tien-Hsing Chen, Yu-Sheng Lin, Su-Ju Lin, Liang-Tseng Kuo, Chi-Lung Chen, Pei-An Yu, Wei-Hsiu Hsu
There is an increased tendency for hip fractures in patients with chronic kidney disease (CKD). Although surgery is the mainstay of treatment for hip fractures, there is scant information on outcomes after hip fracture surgery in diabetic patients at different stages of CKD. In this population-based cohort study, we compared the surgical outcome, readmission, and mortality rates after osteosynthesis of hip fractures in diabetic patients with different stages of renal function. Diabetic patients who received primary osteosynthesis for hip fracture between January 1997 and December 2013 were enrolled...
February 11, 2019: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Yuqiu Ye, Hongyong Liu, Yanbing Chen, Yunqiang Zhang, Shaomin Li, Wentao Hu, Rongqian Yang, Zhesi Zhang, Linsheng Lv, Xun Liu
BACKGROUND: Anemia is extremely common among dialysis patients and underlies some of the symptoms associated with reduced kidney function, including fatigue, depression, reduced exercise tolerance, and dyspnea. OBJECTIVES: A clearer cognition of the prognosistic impact of hemoglobin (Hb) or hematocrit (Hct) target for the outcomes of dialysis patients is urgent. This article aims to establish the suitable hemoglobin in order to provide clinical guidance. METHODS: MEDLINE, EmBase, the Cochrane Library and other databases were searched with both MeSH terms and keywords to gather randomized controlled trials that assessed all-cause mortality, cardiovascular events, fistula thrombosis, infectious diseases and transfusion among dialysis-dependent patients using erythropoiesis-stimulating agents...
November 2018: Renal Failure
Serkan Feyyaz Yalın, Necmi Eren, Ayse Sinangil, Vural Taner Yilmaz, Erhan Tatar, Ali Riza Ucar, Mustafa Sevinc, Özgür Can, Alp Gurkan, Nurol Arik, Sabahat Alisir Ecder, Murathan Uyar, Murat Yasar, Sibel Gulcicek, Meral Mese, Hamad Dheir, Ulkem Cakir, Şimal Köksal Cevher, Kultigin Turkmen, Bahtisen Guven, Dilek Guven Taymez, Banu Erkalma Senates, Tevfik Ecder, Huseyin Kocak, Adam Uslu, Erol Demir, Taner Basturk, Melike Betul Ogutmen, Can Kinalp, Belda Dursun, Zerrin Bicik Bahcebasi, Savas Sipahi, Fatih Dede, Meric Oruc, Yasar Caliskan, Ahmed Genc, Berna Yelken, Mehmet Rıza Altıparmak, Aydin Turkmen, Nurhan Seyahi
BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from lack of alpha-galactosidase A (AGALA) activity in lysosomes. OBJECTIVE: In this multicenter study, we aimed to evaluate the prevalence of FD in renal transplant (Tx) recipients in Turkey. We also screened dialysis patients as a control group. METHODS: All Tx and dialysis patients were screened regardless of the presence of a primary disease. We measured the AGALA activity in all male patients as initial analysis...
February 8, 2019: Nephron
Orit Kliuk-Ben Bassat, Silviu Brill, Haggai Sharon
Significant chronic pain is highly prevalent in chronic kidney disease patients and is associated with morbidity and mortality. In this study, we retrospectively evaluated the incidence and treatment of pain in the dialysis unit of our tertiary referral center. The cohort included 147 patients. Over 66% reported significant (VAS >40) chronic pain during the preceding 3 months, most often characterized as stabbing (38%) and with concurrent itching (44%). Only 33% of patients received chronic pain medications, while 55...
February 8, 2019: Hemodialysis International
Yuhei Otobe, Koji Hiraki, Chiharu Hotta, Kazuhiro P Izawa, Tsutomu Sakurada, Yugo Shibagaki
BACKGROUND: No longitudinal study has investigated the impact of combination of kidney function (KF) and physical function (PF) on cognitive decline in these patients. METHODS: We conducted a 2-year prospective cohort study enrolling 131 patients ≥ 65 years with pre-dialysis chronic kidney disease (CKD). We assessed cognitive function with the Japanese version of the Montreal Cognitive Assessment (MoCA-J). We calculated %MoCA-J based on the rate of change between baseline and follow-up MoCA-J scores, and defined cognitive decline over 2 years as a %MoCA-J of less than the first quartile value...
February 8, 2019: Clinical and Experimental Nephrology
Siyun Xiang, Qiman Jin, Fangyi Xu, Ying Yao, Wangqun Liang, Xuezhi Zuo, Ting Ye, Chenjiang Ying
The present study aims to assess arsenic accumulation and explore its association with renal function and biomarkers of CVD risk in chronic kidney disease patients receiving continuous ambulatory peritoneal dialysis (CAPD). The serum was collected from 87 CAPD patients and 26 healthy subjects between 2015 and 2016. The arsenic concentration was measured by inductively coupled plasma mass spectrometer. Clinical variables related to CVD risk were determined with automatic biochemical analyzer. Serum arsenic was higher in CAPD patients as compared to healthy volunteers...
March 2019: Journal of Trace Elements in Medicine and Biology
Mayumi Asai, Sei Kumakura, Mami Kikuchi
AST-120 (KREMEZIN®) consists of oral, spherical carbon particles that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces. Uremic toxins such as indoxyl sulfate and p-cresyl sulfate are abundant in the blood of chronic kidney disease (CKD) patients and are related to the progression of both CKD and cardiovascular disease. AST-120 was approved in Japan in 1991 followed by Korea (2004), Taiwan (2007) and the Philippines (2010) for treating uremic symptoms and prolonging the time to initiation of dialysis in patients with progressive CKD...
November 2019: Renal Failure
Yasemin Coskun Yavuz, Konca Altınkaynak, Can Sevinc, Saime Ozbek Sebin, Idris Baydar
INTRODUCTION: Cartonectin was defined as a new adipokine released from rat and human adipocyte tissues, which is also known as CORS 26 or CTRP3 protein. Although there are several studies investigating the effects of cartonectin with obesity, anti-inflammatory mechanisms, and cardioprotective effects, there is no study about the effects of cartonectin in patients with chronic kidney disease yet. We aimed to investigate cartonectin levels in predialysis and dialysis patient groups, in other words, at different stages of chronic kidney disease, by comparing with the control group...
November 2019: Renal Failure
Xiaolin Tian, Xiaokun Guo, Xiaoshuang Xia, Haibo Yu, Xin Li, Aili Jiang
BACKGROUNDS: Cognitive functions (CF) decline has been reported in end-stage renal disease (ESRD) patients. However, the influence of dialysis modalities on CF has not been investigated systematically. METHODS: A systematic literature search was conducted in MEDLINE, Embase, Cochrane library and unpublished database to identify the studies comparing the cognitive functions or risk of dementia between hemodialysis (HD) and peritoneal dialysis (PD)...
February 2019: Medicine (Baltimore)
Ruth Dubin, Anna Rubinsky
BACKGROUND: Patient education regarding end-stage renal disease (ESRD) has the potential to reduce adverse outcomes and increase the use of in-home renal replacement therapies. OBJECTIVE: This study aimed to investigate whether an online, easily scalable education program can improve patient knowledge and facilitate decision making regarding renal replacement therapy options. METHODS: We developed a 4-week online, digital educational program that included written information, short videos, and social networking features...
February 6, 2019: JMIR formative research
Joana Gameiro, Inês Duarte, Cristina Outerelo, José António Lopes
Mineral bone disorder is a common feature of chronic kidney disease. Lion face syndrome is rare complication of severe hyperparathyroidism in end-stage renal disease patients, which has been less commonly reported due to dialysis and medical treatment advances in the last decade. The early recognition of the characteristic facial deformity is crucial to prompt management and prevent severe disfigurement. The authors present a rare case of severe hyperparathyroidism presenting with lion face syndrome and bone fractures...
January 21, 2019: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"